Title:
COMPOUND WITH ALK INHIBITORY ACTIVITY AND PREPARATION AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2015/081813
Kind Code:
A1
Abstract:
The present invention relates to a compound with an ALK inhibitory activity and a preparation and use thereof. In particular, the present invention relates to a compound as shown by formula (I) or a pharmaceutically acceptable salt thereof, a preparation method thereof and a use thereof. The compound has the ALK inhibitory activity and can be used for treating cancers which are ALK positive, and thus has a wide prospect in medication.
Inventors:
TONG ZHAOLONG (CN)
SUN XINGYI (CN)
SHENG XIJUN (CN)
ZHANG XIUCHUN (CN)
YU HONGPING (CN)
XU YAOCHANG (CN)
SUN XINGYI (CN)
SHENG XIJUN (CN)
ZHANG XIUCHUN (CN)
YU HONGPING (CN)
XU YAOCHANG (CN)
Application Number:
PCT/CN2014/092492
Publication Date:
June 11, 2015
Filing Date:
November 28, 2014
Export Citation:
Assignee:
SHANGHAI HANSOH BIOMEDICAL CO LTD (CN)
International Classes:
C07D401/14; A61K31/506; A61K31/5377; A61P35/00; C07D401/12; C07D409/14; C07D417/14
Domestic Patent References:
| WO2009126515A1 | 2009-10-15 | |||
| WO2012106540A1 | 2012-08-09 | |||
| WO2011140338A1 | 2011-11-10 | |||
| WO2009032694A1 | 2009-03-12 |
Foreign References:
| CN101616895A | 2009-12-30 |
Other References:
MARSILJE, T.H. ET AL.: "Synthesis, Structure-Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor LDK378 Currently in Phase 1 and Phase 2 Clinical Trials", JOURNAL OF MEDICINAL CHEMISTRY, vol. 56, no. 14, 6 June 2013 (2013-06-06), pages 5675 - 5690, XP055145299, DOI: doi:10.1021/jm400402q
Attorney, Agent or Firm:
GE CHENG & CO., LTD. (CN)
北京戈程知识产权代理有限公司 (CN)
北京戈程知识产权代理有限公司 (CN)
Download PDF: